Glioblastoma: tackling drug resistance to mitotic inhibitors in the brain
Official title: Senescence and Resistance in Glioblastoma
Funded at Mayo Clinic Jacksonville · NIH-11361700 · Data updated 2026-11-12
This project looks at glioblastoma and tests ways to overcome resistance to drugs that disrupt cell division, with a focus on delivering treatments directly to the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | July 15, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $687,314 |
| NIH project number | 1R01CA304198-01A1 |
| Project ID | NIH-11361700 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma could potentially benefit from future brain-delivery strategies and combination therapies explored in this program.
✕Less likely to help
Patients whose tumors do not rely on the studied resistance mechanisms or who are not eligible for brain-directed delivery may not benefit.
What this research studies
Researchers will study why glioblastoma tumors become resistant to anti-mitosis drugs and whether blocking the STAT3 pathway can restore the cancer-killing effect. They will use laboratory models and mouse systems, including immunocompetent and patient-derived models, to test local brain delivery of these drugs combined with STAT3 inhibitors. The work will examine how resistance emerges in relation to apoptosis and how the tumor microenvironment influences response. The study aims to identify combinations that prevent resistance and improve anti-tumor activity without systemic toxicity.
Why it matters
Potential benefit: If successful, the approach could lead to more effective, brain-targeted therapies for glioblastoma with fewer blood-related side effects.
How similar studies have gone: Previous work shows resistance to mitotic inhibitors in glioblastoma can be overcome by targeting the STAT3 pathway, supporting potential benefit for the proposed approach.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Rosenfeld, Steven S — Mayo Clinic Jacksonville
- Study coordinator: Rosenfeld, Steven S
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.